Publications by authors named "Afrah Fatthi Salama"
Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-κB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Gold nanoparticles (AuNPs) have emerged as promising candidates for cancer therapy due to their unique physicochemical properties and biocompatibility. In this study, we investigate the synthesis, characterization, and therapeutic potential of AuNPs in breast cancer treatment. Further, it establishes a comprehensive understanding of the mechanisms by which AuNPs suppress angiogenesis and breast cancer growth, identifying novel targets and signaling nodes contributing to the anti-tumor effects of AuNPs.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the therapeutic effects of gingerol (6-gingerol) and sorafenib on liver cancer (HCC) induced by a chemical called p-Dimethylaminoazobenzene (DAB) in mice, focusing on their impact on specific gene expressions related to cancer.
- Results showed that gingerol reduced oxidative stress markers and improved the expression of tumor suppressor genes while decreasing oncogene levels, suggesting it has potential as an effective therapy for HCC when used alone or in combination with sorafenib.
- The findings indicate that ginger could play a significant role in cancer treatment by modulating oxidative stress and affecting key signaling pathways, which could lead to new
Article Synopsis
- Sorafenib is the only approved drug for treating hepatocellular carcinoma (HCC), and the study investigates the potential of amygdalin, known for its anticancer properties, to work synergistically with Sorafenib against HCC cells.
- Results show that amygdalin selectively kills HepG2 cancer cells while being less toxic to normal cells, and it works together with Sorafenib to enhance cell death through mechanisms involving cell cycle arrest and apoptosis.
- The study suggests amygdalin inhibits the AMPK enzyme, leading to the downregulation of the mTOR and BCL-2 pathways, providing a basis for further research into amygdalin as a promising alternative treatment for HCC.
Cancer cells can become resistant to existing treatments over time, so it is important to develop new treatments that target different pathways to stay ahead of this resistance. Many cancer treatments have severe side effects that can be debilitating and even life-threatening. Developing drugs that can effectively treat cancer while minimizing the risks of these side effects is essential for improving the quality of life of cancer patients.
View Article and Find Full Text PDFArticle Synopsis
- *The study tested diarylheptanoids (DAH) from the plant Alpinia officinarum for their ability to fight HCC in mice, both alone and in combination with an established drug, sorafenib (SOR).
- *Results showed that the combination of DAH and SOR significantly reduced tumor growth and improved liver health, suggesting potential as an effective treatment strategy for HCC.
Environmental contamination by phenol has been reported in both aquatic and atmospheric environments. This study aimed to separate and purify the peroxidase enzyme from bacteria that degrade phenol from wastewater sources. An enrichment culture of MSM was used to screen 25 bacterial isolates from different water samples for peroxidase production, six of the isolates exhibited high levels of peroxidase enzyme activity.
View Article and Find Full Text PDFArticle Synopsis
- Traditional herbal medicine, particularly Thymoquinone (TQ) from black seed and Piperine (PIP) from black pepper, shows promise in enhancing the effects of the cancer drug sorafenib (SOR) against triple-negative breast and liver cancer cells.
- The study utilized various methods like MTT assays and flow cytometry to analyze the cytotoxicity and the mechanisms of action, including effects on DNA methylation and histone acetylation.
- Results indicated that TQ and PIP combined with SOR led to increased cancer cell death and growth inhibition by downregulating certain oncogenic proteins and upregulating tumor suppressor miRNA-29c, while molecular docking studies confirmed strong interactions among these compounds.
The burden of cancer diseases is increasing every year, therefore, the demands to figure out novel drugs that can retain antitumor properties have been raised. This study aimed to investigate the anti-tumor properties of amygdalin (Amy) against Ehrlich ascites carcinoma (EAC) bearing mice and its protective properties against liver damage. Amy and the standard anticancer drug Sorafenib (Sor) were given alone or in combination to Swiss albino female mice that had been injected with EAC cells.
View Article and Find Full Text PDF